title: [Loss of bone mass in patients with prostate cancer subjected to androgenic deprivation].
abstract: BACKGROUND
  Treatment based on androgenic deprivation is one of the standard treatments that many prostate cancer patients receive. Moreover, its use is increasing due to a clear expansion of the indications of this therapy in patients with localized cancer.
  
  
  METHODS
  In spite of being classically considered that it is well tolerated, androgenic deprivation has adverse effects. Of these, it is worth mentioning the loss of mineral bone mass, which can lead to osteoporosis and increase the risk of bone fracture. Some fractures may have serious consequences, as occurs with hip fractures. To make a diagnosis in this situation, there are useful procedures such as bone densitometry. Once diagnosed, the decrease in mineral bone mass can be managed with dietary recommendations, general changes in lifestyle, or with drugs such as denosumab.
  
  
  CONCLUSIONS
  Following applicable recommendations, urologists must carefully monitor the bone health of patients with prostate cancer subjected to androgenic deprivation, in order to obtain an early diagnosis and to apply the appropriate general and/or therapeutic measures, if necessary.
authors.affiliation: Servicio de Urología, Hospital Vall d'Hebron, Universidad Autónoma de Barcelona, España. jmorote@vhebron.net
authors.forename: J
authors.initials: J
authors.lastname: Morote
authors.forename: J
authors.initials: J
authors.lastname: Planas
mesh_terms: D015502:Absorptiometry, Photon; D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000728:Androgens; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D016207:Cytokines / Q000502:physiology; D004164:Diphosphonates / Q000627:therapeutic use; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000150:complications / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D009919:Orchiectomy / Q000009:adverse effects; D010010:Osteoclasts / Q000502:physiology; D010024:Osteoporosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D017410:Practice Guidelines as Topic; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D018931:Antineoplastic Agents, Hormonal; D050071:Bone Density Conservation Agents; D016207:Cytokines; D004164:Diphosphonates